New research has identified three critical findings that should inform supplement decisions for individuals concerned about cognitive health. First, glucosamine users with mild cognitive impairment face a 25% higher risk of progressing to Alzheimer’s disease—a substantial increase warranting medical attention. Second, the mechanisms linking this supplement to cognitive decline appear to involve inflammatory pathways in the brain, suggesting the risk is biologically plausible rather than coincidental.
Third, and perhaps most important, this widely-used over-the-counter supplement’s safety profile requires reassessment. Many patients assume joint supplements carry no neurological risks, but these findings challenge that assumption.
For individuals taking glucosamine—particularly those with existing cognitive concerns or family history of dementia—consultation with healthcare providers is essential to weigh potential joint benefits against emerging brain health risks.
Read the full article on GMJ Newsroom.
Was this article helpful?
